This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.06.080v1 46/10/1792    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (61) Citing Articles via Google Scholar Google Scholar Articles by Ansell, B. J. Articles by Fonarow, G. C. Search for Related Content PubMed PubMed Citation Articles by Ansell, B. J. Articles by Fonarow, G. C.

STATE-OF-THE-ART PAPER

High-Density Lipoprotein Function

Recent Advances

Atherosclerosis Research Unit, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

Manuscript received April 24, 2005; revised manuscript received May 29, 2005, accepted June 7, 2005.

^_* Reprint requests and correspondence: Dr. Gregg C. Fonarow, 47-123 CHS, 10833 LeConte Avenue, Los Angeles, California 90095. (Email: gfonarow{at}mednet.ucla.edu).

Although high-density lipoproteins (HDL) possess many features that contribute to the association between elevated HDL cholesterol and protection from atherosclerosis, these lipoproteins may be modified in certain individuals and/or circumstances to become proinflammatory. The ability of HDL to inhibit or paradoxically to enhance vascular inflammation, lipid oxidation, plaque growth, and thrombosis reflects changes in specific enzyme and protein components. The anti-inflammatory and proinflammatory functional properties of HDL can now be assessed using cell-based and cell-free assays. Acute or chronic systemic inflammation and the metabolic syndrome appear to render HDL proinflammatory. In contrast, statins and experimental agents such as apolipoprotein A-1 mimetics render HDL more anti-inflammatory. Functional characterization of HDL is a promising method for enhanced assessment of cardiovascular risk and effectiveness of risk reduction.

Abbreviations and Acronyms   ABCA1 = adenosine triphosphate-binding cassette transporter A1   apoA-1 = apolipoprotein A-1   CETP = cholesteryl ester transfer protein   CFA = cell-free assay   CHD = coronary heart disease   HDL = high-density lipoprotein   HDL-C = high-density lipoprotein cholesterol   LDL = low-density lipoprotein   MCA = monocyte chemotaxis assay   MCP = monocyte chemotaxis protein   ox-LDL = oxidized low-density lipoprotein

This article has been cited by other articles:

				M. Cesari, E. Marzetti, A. Laudisio, L. Antonica, M. Pahor, R. Bernabei, and G. Zuccala Interaction of HDL cholesterol concentrations on the relationship between physical function and inflammation in community-dwelling older persons Age Ageing, November 5, 2009; (2009) afp194v1. [Abstract] [Full Text] [PDF]

				M. J. Chapman, W. Le Goff, M. Guerin, and A. Kontush Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J., October 12, 2009; (2009) ehp399v1. [Abstract] [Full Text] [PDF]

				B. Zhang, A. Matsunaga, D. L. Rainwater, S.-i. Miura, K. Noda, H. Nishikawa, Y. Uehara, K. Shirai, M. Ogawa, and K. Saku Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study J. Lipid Res., September 1, 2009; 50(9): 1832 - 1841. [Abstract] [Full Text] [PDF]

				R. Franssen, R. R. Sankatsing, E. Hassink, B. Hutten, M. T. Ackermans, K. Brinkman, R. Oesterholt, A. Arenas-Pinto, S. P. Storfer, J. J. Kastelein, et al. Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1336 - 1341. [Abstract] [Full Text] [PDF]

				M. Briel, I. Ferreira-Gonzalez, J. J You, P. J Karanicolas, E. A Akl, P. Wu, B. Blechacz, D. Bassler, X. Wei, A. Sharman, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ, February 16, 2009; 338(feb16_1): b92 - b92. [Abstract] [Full Text] [PDF]

				G. Ferns and V. Keti HDL-cholesterol modulation and its impact on the management of cardiovascular risk Ann Clin Biochem, March 1, 2008; 45(2): 122 - 128. [Abstract] [Full Text] [PDF]

				S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]

				I. M. Singh, M. H. Shishehbor, and B. J. Ansell High-Density Lipoprotein as a Therapeutic Target: A Systematic Review JAMA, August 15, 2007; 298(7): 786 - 798. [Abstract] [Full Text] [PDF]

				U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]